Healthcare / BiotechnologyNasdaqGS
$16.21
-0.23 (-1.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-145.3M · quality 68.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$996M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-53.8%
↓Gross Margin
N/A
•Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-219.9M · FCF $-175.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | — | — | — | — | — | $18.9M | $0.00 |
| Net Income | $-219.9M | $-219.9M | $-167.4M | $-153.2M | $111.2M | $-65.6M | $-51.8M |
| EBITDA | $-241.3M | $-241.3M | $-196.6M | $-190.3M | $-132.0M | $-67.9M | $-60.3M |
| EPS | — | — | -2.78 | -3.21 | 2.38 | -1.52 | — |
| Operating Margin | — | — | — | — | — | -358.7% | — |
| Net Margin | — | — | — | — | — | -346.1% | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | — | — |
| Current Ratio | 10.28 | 10.28 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-175.8M | $-175.8M | $-145.3M | $-134.5M | $-127.8M | $-43.4M | $-29.8M |
| Returns | |||||||
| ROE | -53.8% | -53.8% | -28.4% | -33.8% | 20.8% | -15.4% | -26.0% |
| Valuation | |||||||
| P/E | — | — | — | — | 4.57 | — | — |
| P/B | 2.39 | 2.39 | 1.15 | 0.93 | 0.95 | — | — |
| Growth & Yield | |||||||
| EPS Growth | — | — | 13.4% | -234.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+87.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.78 → n/d
Residual
+87.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.